Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. (2021). Voprosy Onkologii, 67(5), 665-674. https://doi.org/10.37469/0507-3758-2021-67-5-665-674